Relay Therapeutics, Inc. (RLAY)
18.96
+0.47
(+2.54%)
USD |
NASDAQ |
Oct 02, 16:00
18.63
-0.33
(-1.74%)
After-Hours: 20:00
Relay Therapeutics Max Drawdown (5Y) : 96.75% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.75% |
| August 31, 2026 | 96.75% |
| July 31, 2026 | 96.75% |
| June 30, 2026 | 96.75% |
| May 31, 2026 | 96.75% |
| April 30, 2026 | 96.75% |
| March 31, 2026 | 96.75% |
| February 28, 2026 | 96.75% |
| January 31, 2026 | 96.75% |
| December 31, 2025 | 96.75% |
| November 30, 2025 | 96.75% |
| October 31, 2025 | 96.75% |
| September 30, 2025 | 96.75% |
| August 31, 2025 | 96.75% |
| July 31, 2025 | 96.75% |
| June 30, 2025 | 96.75% |
| May 31, 2025 | 96.75% |
| April 30, 2025 | 96.75% |
| March 31, 2025 | 95.74% |
| February 28, 2025 | 94.72% |
| January 31, 2025 | 93.81% |
| December 31, 2024 | 93.30% |
| November 30, 2024 | 92.46% |
| October 31, 2024 | 90.84% |
| September 30, 2024 | 90.41% |
| Date | Value |
|---|---|
| August 31, 2024 | 90.41% |
| July 31, 2024 | 90.41% |
| June 30, 2024 | 90.41% |
| May 31, 2024 | 90.41% |
| April 30, 2024 | 90.41% |
| March 31, 2024 | 90.23% |
| February 29, 2024 | 90.23% |
| January 31, 2024 | 90.23% |
| December 31, 2023 | 90.23% |
| November 30, 2023 | 90.23% |
| October 31, 2023 | 90.23% |
| September 30, 2023 | 86.61% |
| August 31, 2023 | 83.89% |
| July 31, 2023 | 83.76% |
| June 30, 2023 | 83.76% |
| May 31, 2023 | 83.76% |
| April 30, 2023 | 81.64% |
| March 31, 2023 | 78.37% |
| February 28, 2023 | 78.37% |
| January 31, 2023 | 78.37% |
| December 31, 2022 | 78.37% |
| November 30, 2022 | 78.37% |
| October 31, 2022 | 78.37% |
| September 30, 2022 | 78.37% |
| August 31, 2022 | 78.37% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| SELLAS Life Sciences Group, Inc. | 99.91% |
| Karyopharm Therapeutics, Inc. | 99.44% |
| Spyre Therapeutics, Inc. | 99.04% |
| Akebia Therapeutics, Inc. | 98.61% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -31.59 |
| Beta (5Y) | 1.724 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 74.33% |
| Historical Sharpe Ratio (5Y) | -0.1929 |
| Historical Sortino (5Y) | -0.4043 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 28.63% |